个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Wang C[1,*1] ; Chen K-N[2] ; Chen Q[3] ; Wu L[4] ; Wang Q[5] ; Li X[6] ; Ying K[7] ; Wang W[4] ; Zhao J[8] ; Liu L[9] ; Fu J[10] ; Zhang C[11] ; Liu J[12] ; Hu Y[13] ; Ntambwe I[14] ; Cai J[14] ; Bushong J[14] ; Tran P[14] ; Lu S[15,*2] ;
机构： [1]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Electronic address: wangchangli@tjmuch.com. [2]Peking University Cancer Hospital and Institute, Beijing, China. [3]Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China. [4]Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. [5]Zhongshan Hospital and Fudan University, Shanghai, China. [6]Tangdu Hospital, Xi'an, China. [7]Sir Run Run Shaw Hospital, Hangzhou, China. [8]Cancer Center of Guangzhou Medical University, Guangzhou, China. [9]West China Hospital of Sichuan University, Chengdu, China. [10]The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. [11]Xiangya Hospital of Central South University, Changsha, China. [12]The Second Affiliated Hospital of Nanchang University, Nanchang, China. [13]Chinese People's Liberation Army General Hospital (301 Hospital), Beijing, China. [14]Bristol Myers Squibb, Princeton, NJ, USA. [15]Shanghai Chest Hospital and Shanghai Jiao Tong University, Shanghai, China. Electronic address: shun_lu@hotmail.com.
出处：
DOI： 10.1016/j.esmoop.2023.102040

摘要：
Neoadjuvant nivolumab plus chemotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) versus chemotherapy alone in patients with resectable non-small-cell lung cancer (NSCLC) in the global phase III CheckMate 816 study. Here, we report post hoc exploratory efficacy, safety, and surgical outcomes in the Chinese subpopulation of this study.Adults with stage IB-IIIA resectable NSCLC were randomized to receive nivolumab 360 mg plus chemotherapy or chemotherapy alone every 3 weeks for three cycles followed by surgery. Primary endpoints included EFS and pCR (both per blinded independent review). EFS and pCR results were from 14 October 2022, and 16 September 2020, database locks, respectively.The Chinese subpopulation comprised 97 patients (nivolumab plus chemotherapy, 44; chemotherapy, 53). At 38.2 months of minimum follow-up, median EFS was not reached [95% confidence interval (CI) 23.4 months-not reached] in the nivolumab plus chemotherapy arm and 13.9 months (95% CI 8.3-34.3 months) in the chemotherapy arm (hazard ratio 0.47, 95% CI 0.25-0.88). pCR rates were 25.0% (95% CI 13.2% to 40.3%) and 1.9% (95% CI 0.0% to 10.1%), respectively (odds ratio 11.05; 95% CI 1.41-86.49). Of 97 Chinese patients, 36 (82%) in the nivolumab plus chemotherapy arm and 41 (77%) in the chemotherapy arm underwent definitive surgery. Grade 3-4 treatment-related adverse events occurred in 18/43 patients (42%) treated with nivolumab plus chemotherapy and 22/53 patients (42%) treated with chemotherapy.Consistent with findings in the global study population of CheckMate 816, neoadjuvant nivolumab plus chemotherapy improved EFS and pCR versus chemotherapy in the Chinese subpopulation without impacting treatment tolerability or the feasibility of surgery. These findings support the use of nivolumab plus chemotherapy as a standard neoadjuvant treatment option for Chinese patients with resectable NSCLC.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

基金：
This work was supported by Bristol Myers Squibb (no grant number).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
第一作者：
第一作者机构： [1]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Electronic address: wangchangli@tjmuch.com. [*1]Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China.
通讯作者：
通讯机构： [1]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Electronic address: wangchangli@tjmuch.com. [15]Shanghai Chest Hospital and Shanghai Jiao Tong University, Shanghai, China. Electronic address: shun_lu@hotmail.com. [*1]Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, He Xi District, Tianjin 300060, China. [*2]Shanghai Chest Hospital and Shanghai Jiao Tong University, 241 West Huaihai Road, Xuhui District, Shanghai 200030, China.
推荐引用方式(GB/T 7714)：
Wang C,Chen K-N,Chen Q,et al.Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816[J].ESMO open.2023,8(6):102040.doi:10.1016/j.esmoop.2023.102040.
APA：
Wang C,Chen K-N,Chen Q,Wu L,Wang Q...&Lu S.(2023).Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816.ESMO open,8,(6)
MLA：
Wang C,et al."Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816".ESMO open 8..6(2023):102040

资源点击量：46425 今日访问量：0 总访问量：3323 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号